Novo-ZymoGenetics: The Next Roche-Genentech?
Date: Jul 01, 2007
Author: Melanie Senior
Source: invivo ( click here to go to the source)
Executive Summary
Novo Nordisk's decision to spin off ZymoGenetics in 2000 was 100% inspired by Roche's hands-off relationship with Genentech. The parent claims Zymo's R&D productivity has since increased; its recent ex-US deal with Bayer-Schering on recombinant thrombin proves that Zymo has certainly grown up and left home.
Author: Melanie Senior
Source: invivo ( click here to go to the source)
Featured firm in this article: Zymogenetics Inc of Seattle, WA
 |
Novo Nordisk's decision to spin off ZymoGenetics in 2000 was 100% inspired by Roche's hands-off relationship with Genentech. The parent claims Zymo's R&D productivity has since increased; its recent ex-US deal with Bayer-Schering on recombinant thrombin proves that Zymo has certainly grown up and left home.
Recent News
 |
 |
 |
 |
